Stockwinners Market Radar for February 10, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:08 EST AeroVironment awarded $8.6M military sales contract - AeroVironment announced it received a $8,584,734 firm-fixed-price U.S. Department of Defense Foreign Military Sales contract. The contract was awarded on December 17, 2019 to provide Puma(TM) 3 AE unmanned aircraft systems, training and support to an allied nation. Delivery is anticipated by June 2020.

18:41 EST Fly Intel: After Hours Movers - UP AFTER EARNINGS: Amkor (AMKR) up 16.7%... Fluidigm (FLDM) up 13.2%... OneMain Holdings (OMF) up 3.8%... RingCentral (RNG) up 3.4%... XPO Logistics (XPO) up 2.6%... Brighthouse Financial (BHF) up 2.0%... Steris (STE) up 2.0%. ALSO HIGHER: Spring (S) up 54.0%, T-Mobile (TMUS) up 7.7% after getting judge's approval to complete merger... Oceaneering (OII) up 3.8% after getting light well intervention contract from BP... Avrobio (AVRO) up 2.2% after positive initial data on its Cystinosis program. DOWN AFTER EARNINGS: Genasys (GNSS) down 7.7%... Callaway Golf (ELY) down 6.6%... Digital Turbine (APPS) down 6.4%... Radiant Logistics (RLGT) down 6.3%... Rapid7 (RPD) down 5.4%... Chegg (CHGG) down 4.3%... MercadoLibre (MELI) down 3.9%... Brixmor Property (BRX) down 3.8%... Mimecast (MIME) down 3.7%... Albany International (AIN) down 3.0%... Molina Healthcare (MOH) down 2.6%... Varonis (VRNS) down 2.4%... II-VI (IIVI) down 1.7%... Kemper (KMPR) down 1.4%. ALSO LOWER: LogicBio (LOGC) down 26.3% after FDA placed clinical hold on submission of LB-001... Xeris Pharma (XERS) down 7.5% after equity offering... Revance Therapeutics (RVNC) down 5.3% after convertible debt offering... Theravance Biopharma (TBPH) down 5.2% after equity offering... Adverum Biotech (ADVM) down 3.7% after equity offering. Movers as of 18:30ET.

18:24 EST Take-Two CEO: We are doing well - In an interview on CNBC's Mad Money, Take-Two CEO Strauss Zelnick discussed the company's recent quarterly results. Zelnick said, "There was mostly good news in the quarter. The market has gotten very used to us beating guidance and we were in the middle." He added that the company's WWE offering was a "weak spot" and that they can do better going forward. In summarizing the quarter, Zelnick said, "We mostly executed, but not across the board. We have more to do."

18:17 EST Essa Pharma discloses several EPI-7386 abstracts selected for ASCO presentation - ESSA Pharma announced that several abstracts on ESSA's lead clinical candidate, EPI-7386, have been selected for presentation at upcoming medical and scientific symposia. These presentations will provide further preclinical characterization of EPI-7386 including new preclinical data regarding safety studies, gene expression and combination data with antiandrogens.

17:57 EST Aerojet Rocketdyne awarded $19.6M DARPA contract - Aerojet Rocketdyne has been awarded a contract worth up to $19.6M by the Defense Advanced Research Projects Agency, or DARPA, to develop enabling technologies for an advanced hypersonic defense interceptor known as Glide Breaker.

17:55 EST YayYo Inc trading resumes

17:30 EST Compass Minerals sees FY20 EBITDA $350M-$400M - Sees FY20 CapEx $100M-$110M.

17:17 EST GenMark CEO Hany Massarany steps down, Scott Mendel named interim CEO - GenMark Diagnostics announced that Scott Mendel, COO, has been appointed Interim President and CEO, effective immediately. Hany Massarany has stepped down as President and CEO and as a member of the company's Board of Directors, effective immediately. A search has commenced to identify a permanent CEO. Concurrently Kevin O'Boyle has been appointed Chairman of the Board and James Fox, PhD., GenMark's prior Chairman, will remain on the Board as a non-executive director. Mendel has served as GenMark's COO since February 2019. Previously, he served as CFO since joining the company in 2014. Prior to joining GenMark, Mendel held various roles of increasing responsibility at The Active Network and GE Healthcare.

17:14 EST NextDecade says Rio Grande facility authorized to export liquefied natural gas - NextDecade announced that the U.S. Department of Energy has issued an order granting authorization to export liquefied natural gas from its Rio Grande LNG facility to non-free trade agreement countries. In combination with a free trade agreement order previously issued in August 2016, NextDecade is now authorized to export LNG equivalent to 1,318 billion cubic feet of natural gas per year from Rio Grande LNG to both FTA and non-FTA countries.

17:08 EST Copa Holdings reports January traffic down 5.7%, capacity down 7% - As a result, system load factor for the month was 84.2%, 1.2 percentage points higher than January 2019.

17:06 EST Oceaneering awarded riserless light well intervention contract by BP - Oceaneering (OII) announced the award by units of BP (BP), of a contract to provide comprehensive riserless light well intervention services offshore Angola in Blocks 18 and 31. The value of this meaningful award is reflected in our December 31, 2019 Subsea Products backlog. In connection with this contract, Oceaneering has agreed to provide personnel and equipment related to its RLWI services, remotely operated vehicles, survey services, and communication services integrated onto a chartered multi-purpose vessel. These services are contracted to support a multi-well campaign designed to include mechanical well interventions, well stimulations, and tree change-outs. Oceaneering's work scope also includes project management, engineering, systems integration, offshore management, and project crews. Offshore operations are scheduled to begin in the second quarter, with completion anticipated in the late fall of 2020.

17:03 EST Tyson Foods and oleochemicals distributor Jacob Stern in joint venture - Tyson Fresh Meats, and Jacob Stern & Sons have launched a joint venture, JST Global to serve the worldwide fats and oils market. Specific terms of the venture are not being disclosed. Beef and pork by-products of the fresh meats business, along with fats and oils derived from other sources, are key ingredients in thousands of products in such diverse industries as pharmaceuticals, personal care, and animal nutrition, plus the rapidly developing field of renewable fuels."Jacob Stern and Tyson Fresh Meats have enjoyed a strong relationship for over 50 years. Combining Tyson's vast supply of animal fats with Jacob Stern's Texas operations is a natural evolution and positions JST Global to meet growing worldwide demand," said Phil Bernstein, Chairman, Jacob Stern & Sons.Tyson Fresh Meats, based in Dakota Dunes, SD, currently operates six beef plants and six pork plants in the U.S. Jacob Stern & Sons is among Tyson's largest customers for animal by-products and is the largest U.S. processor and marketer of animal fats.

16:59 EST Agile Therapeutics 3% jumps after announcing $35M loan facility with Perceptive - Agile Therapeutics announced that it has entered into a senior secured term loan credit facility with Perceptive Advisors to provide Agile with up to $35M through term loans in three tranches. $5M was funded after the satisfaction of customary closing conditions, $15M will be available if Twirla is approved by the U.S. Food and Drug Administration, and $15M will be available upon the achievement of certain revenue milestones. Agile is permitted to make interest only payments on the loan until February 2023. "This strategic debt financing coupled with our current cash increases our balance sheet strength and positions us well to continue our commercialization strategy for Twirla, with an expected FDA decision less than one week away," stated Al Altomari, Chairman and Chief Executive Officer of Agile. Mr. Altomari continued, "We expect that our existing estimated cash on hand as of December 31, 2019, and the $20 million in loan proceeds which we would be eligible to receive upon the FDA's approval of Twirla will allow us to fund our operations through the end of 2020. We are pleased to have the support from Perceptive, which is a recognized leader in growth capital financing." In connection with the credit agreement, Agile issued Perceptive warrants to purchase 1,400,000 shares of Agile common stock. The per share exercise price for 700,000 shares is $3.74, which is equal to the 5 day volume weighted average price as of the trading day immediately prior to closing. The per share exercise price for the remaining 700,000 shares of Agile common stock is $4.67, which is equal to 1.25 times the 5 Day VWAP. Shares are up 3.25% to $4.14 in late trading.

16:51 EST Callaway Golf down 8% to $19.00 after issuing weak Q1, FY20 guidance

16:44 EST MercadoLibre falls over 8% after quarterly report - Shares are currently down over 8% in after-hours trading on Monday to $605 per share.

16:41 EST Burlington Stores announces launch of debt repricing - Burlington Stores announced the launch of a debt repricing transaction and provided updated guidance for the fourth quarter and fiscal year ended February 1, 2020. Launch of Debt Transaction. The Company is seeking an amendment to its $961 million senior secured term loan credit facility that matures in 2024 in order to reduce the LIBOR interest rate margin from 2.00% to 1.75%, while maintaining a 0.00% LIBOR floor.

16:38 EST Slack Technologies says not updating financial guidance for Q4

16:36 EST Callaway Golf CEO says 'coronavirus will impact our business' - "Looking forward to 2020, the outbreak of the coronavirus will impact our business with regard to sales in Asia and on the supply side," added CEO Brewer. "The financial guidance we provided today reflects our best estimate of the impact of this outbreak on our business. It is very difficult, however, to provide an estimate with any degree of certainty given the dynamic nature of this crisis. Our thoughts and prayers are with the people of China, including our employees, customers and their families in that region, as well as those affected by the virus globally. We hope and pray for a speedy resolution." Brewer continued, "While the coronavirus, tariffs and foreign currency rates will provide headwinds in 2020, we are looking forward to another strong year of operational performance with growth in both our golf equipment and soft goods segments. We also intend to make additional investments in our business in furtherance of our corporate strategy of making Callaway a larger and more diverse company with higher embedded growth prospects and long-term earnings outlook."

16:34 EST GAIN Capital reports January operating metrics - In the retail segment in January, OTC Trading Volume was up 23.4% sequentially and down 12.3% y/y. OTC Average Daily Volume was up 17.7% sequentially and down 13.1% y/y. 12 Month Trailing Active OTC Accounts were up 0.7% sequentially and were up 0.7% y/y. 3 Month Trailing Active OTC Accounts were up 0.1% sequentially and up 4.0% y/y.

16:33 EST Mid-Southern Bancorp announces Robert DeRossett CFO - Mid-Southern Bancorp, the holding company for Mid-Southern Savings Bank, FSB announced that Robert W. DeRossett has been hired as Chief Financial Officer of the Company effective February 5, 2020. Mr. DeRossett, a CPA and CFA brings over twenty-five years of experience and adds significant expertise to the Company's financial management and reporting areas.

16:32 EST Leidos forms Scientific Advisory Board - Leidos announced the formation of a Scientific Advisory Board for its Explorations in Global Health division within the Leidos Health Group. The ExGloH SAB is an esteemed group of experts in oncology and drug development chosen to advance ExGloH in its development of their pre-clinical pipeline of peptide-based immune modulators. ExGloH is dedicated to developing new immunotherapies for cancer and infectious diseases. ExGloH SAB members will work closely with ExGloH leadership to evolve the pre-clinical development of its lead drug candidate LD10, a novel peptide-based, immuno-modulator for the treatment of cancer and infectious diseases.

16:30 EST TTEC Holdings acquires Serendebyte, terms not disclosed - TTEC Holdings announced that it has acquired a majority interest in Serendebyte, "an intelligent automation CX solutions provider." Serendebyte helps companies transform their customer and employee experiences by improving sales process automation, customer service, marketing automation and operations/compliance for large enterprises.

16:28 EST Grinrod Shipping acquires additional 33.25% stake in IVS Bulk JV - Grindrod Shipping announced a number of transactions relating to the acquisition of an additional 33.25% stake in its IVS Bulk joint venture, or JV, and the sale of the 2010-built small product tanker Kowie. A subsidiary of the company, Grindrod Shipping Pte, or GSPL, has agreed to acquire the 33.25% ordinary and preferred equity shares held by one of its two JV partners in IVS Bulk for a total consideration of $44.1M, thereby increasing its stake to 66.75%. The ordinary equity portion will be acquired for $35M while the preferred equity component will be $9.1 million representing that partner's 33.25% share of the $27.3 million preferred share capital in IVS Bulk. The acquisition will be funded through a combination of cash on hand, proceeds received from a refinancing of the IVS Bulk capital structure, and a new loan at GSPL, as summarized below. The agreements are subject to customary closing conditions with an estimated closing date of February 14. We can provide no assurance that we will complete the acquisition until such time that the agreements have been executed and implemented. In conjunction with the acquisition, GSPL will enter into a revised shareholders agreement with the remaining 33.25% partner in IVS Bulk that will extend the partnership for a further committed period of 12 months and will result in GSPL controlling key aspects of corporate governance of the JV. As a result, the financials of IVS Bulk will be consolidated into the financial statements of Grindrod Shipping Holdings going forward rather than being accounted for under the equity accounting method, as has previously been the case. In order to optimize its capital structure, IVS Bulk has agreed comprehensive refinancing agreements with its lenders. The two existing credit facilities of IVS Bulk will be refinanced with two new senior secured loans totaling $127.3M, representing an approximate 55% loan-to-value at drawdown with maturity scheduled for 2025. The company is included as a borrower under one of these facilities. A portion of the proceeds of the new senior secured loans will be used by IVS Bulk to repay the existing shareholder loans in the JV in full and redeem a portion of the preferred share capital of IVS Bulk pro rata. These transactions will occur prior to the acquisition by GSPL of the 33.25% stake from one of its two JV partners. In addition, GSPL has agreed to a new financing in the amount of $35.8M with an affiliate of the remaining partner in IVS Bulk. This financing matures in June 2021 and is secured by GSPL's equity stake in the JV. Further details regarding the transaction will be shared in the year-end earnings release and presentation scheduled for later this month. Separately, a subsidiary of the company has contracted to sell to an unaffiliated third party the 2010-built small product tanker Kowie for a gross price of $9.2M. The vessel is expected to deliver to its new owners during February. We can provide no assurance that we will complete the sale of the vessel until such time that delivery has occurred.

16:26 EST Resideo acquires Herman ProAV, terms not disclosed - Resideo Technologies announced it has acquired privately held Herman ProAV, based in Miramar, Fla. The newly acquired company is "a leading provider and distributor of professional audio-visual products, procurement services and labor resources to systems integrators in the commercial audio-visual industry." Herman ProAV serves customers across the United States and will be part of Resideo's ADI Global Distribution business, a leading wholesale distributor of security, AV and low-voltage products.

16:20 EST Banc of California announces $45M share repurchase program

16:19 EST Digital Turbine to acquire Mobile Posse for $66M - Digital Turbine announced that it has entered into a definitive purchase agreement to acquire Mobile Posse, a mobile content discovery and advertising platform company headquartered in Arlington, VA., for an estimated total of $66M: (1) $41.5M in cash to be paid at closing, subject to purchase price adjustments, and (2) an estimated earn-out of $24.5M, to be paid in cash, based on Mobile Posse achieving certain future target net revenues, less associated revenue shares, over a twelve-month period following the closing, noting that the earn-out amount is subject to change based on final results and calculation. The initial cash consideration of $41.5M will be funded by a combination of cash on hand and debt. The acquisition of Mobile Posse, which is fully consistent with Digital Turbine's expressed strategy to provide a comprehensive media and advertising solution for our operator and OEM partners while enriching the mobile experience for end users by delivering highly relevant content to their fingertips, is expected to close in the company's fiscal fourth quarter.

16:06 EST Repay Holdings announces acquisition of Ventanex for up to $50M - Repay Holdings announced the acquisition of Ventanex for up to $50M, of which $36 million was paid at closing. The remaining $14 million may become payable upon the achievement of performance growth targets. The closing of the acquisition was financed with a combination of cash on hand and new borrowings under REPAY's existing credit facility. As part of the financing for the transaction, REPAY has entered into an agreement with Truist Bank and other members of its existing bank group to amend and upsize its existing credit facility by $115 million to provide additional capacity for growth.

16:04 EST Amkor Technology sees FY20 CapEx around $550M

16:02 EST Covenant Transportation announces up to $20M stock repurchase plan - Covenant Transportation announced that its board has approved a stock repurchase program authorizing the purchase of up to $20M of the company's Class A common stock from time-to-time based upon market conditions and other factors. The stock may be repurchased on the open market or in privately negotiated transactions. The repurchased shares will be held as treasury stock and may be used for general corporate purposes as the board may determine. The company did not place a limit on the duration of the repurchase program. The stock repurchase program does not obligate the company to repurchase any specific number of shares and the company may suspend or terminate the program at any time without prior notice.

16:01 EST SolarEdge announces receipt of JET certification for single phase inverter - SolarEdge Technologies announced that its single phase inverter with HD-Wave technology received JET certification. Specifically designed to comply with Japanese market requirements, the inverter is now available for low-voltage commercial and residential PV installations. The JET certification extends for five years and covers the new anti-islanding function requirements for multiple inverters and reactive power oscillation suppression. With a long-term commitment to the Japanese market, SolarEdge said in a statement that it has opened a technical and testing center in Yokohama that evaluates the grid protection function of SolarEdge inverters according to JEC9701 and JET certification test methods. "SolarEdge's JET certified 5.5kW single phase inverter with HD-Wave technology has increased power density, record-breaking 99% weighted efficiency, and a competitively small size and weight, at only 12.3kg. The inverter has a 0.95 power factor, supports up to 200% oversizing for increased production, and features SolarEdge's built-in SafeDC for enhanced safety."

16:00 EST LogicBio Therapeutics Inc trading halted, news pending

15:49 EST Slack trading halted, news pending

15:15 EST Can-Fite BioPharma trading resumes

14:37 EST DPW Holdings announces exchange agreement for debt totaling $7.7M - DPW Holdings announced that it has entered into a Master Exchange Agreement dated February 10 with a family office to resolve debt previously in default in an aggregate amount of up to $7.7M. The family office has purchased $4.2M of outstanding debt currently in default and has committed to purchase up to an additional $3.5M of outstanding debt upon receipt of stockholder approval. In connection with the entry into the agreement, Dominion Capital has sold its secured promissory note to the family office, as has another creditor, of which the notes in the hands of the family office are no longer in default, and all litigation between the parties is resolved. The remaining note holders have entered into forbearance agreements and, upon receipt of stockholder approval, the family office has agreed to acquire the debt held by these parties. DPW's CEO and Chairman, Milton "Todd" Ault, III said, "Today's announcement represents a significant milestone for DPW. As a significant stockholder, I am now much more confident in the company's future as much uncertainty has been removed. Our supportive partners worked diligently with us to structure these transactions, and I am proud of our team's persistence in getting this transaction consummated. We are pleased to report that as a result of the closing of the exchange agreement, litigation related to our senior secured creditor has been dropped. The exchange agreement has not only eliminated debt that was in default, but will improve our financial results by reducing the company's borrowing costs and will also enable management to focus on the many opportunities we have to grow our business, which was challenging in light of the constraints under our prior debt agreements."

14:29 EST Digital Power trading halted, news pending

13:31 EST UPS, Pilots reach tentative agreement on two-year contract extension - The Independent Pilots Association and UPS Airlines announced a tentative agreement on a new two-year contract extension. The short term agreement provides for contract improvements in compensation and retirement. Specific details of the agreement will not be disclosed before the IPA presents the proposed contract to all UPS pilots. The contract must be ratified by a majority of UPS's pilots. The vote by the pilots will be completed on March 31. If ratified, the new agreement will extend the IPA's contract with UPS to September 1, 2023.

13:00 EST Capital Research Global Investors discloses 18% stake in Luckin Coffee - In a regulatory filing, Capital Research Global Investors, a division of Capital Research and Management Company, disclosed that it holds sole voting power for 60,322,272 shares of Luckin Coffee stock, of 18% of the 334,734,912 shares believed to be outstanding. All shares held by CRGI are American Depositary Shares, representing 8 Ordinary Shares, the filing stated.

12:07 EST Epizyme strength attributed to NCCN recommendation - Trading contacts tell The Fly that strength in shares of Epizyme is related to a recommendation related to the company's tazemetostat drug being issued by the National Comprehensive Cancer Network, or NCCN. Information about the NCCN's treatment guidelines is only available to users with a site login. Near midday, shares of Epizyme are up 99c, or 4.6%, to $22.34. Reference Link

12:00 EST Biohaven Pharmaceutical falls -12.2% - Biohaven Pharmaceutical is down -12.2%, or -$6.25 to $45.00.

12:00 EST Maui Land & Pineapple rises 18.9% - Maui Land & Pineapple is up 18.9%, or $2.00 to $12.56.

12:00 EST Taubman Centers rises 53.2% - Taubman Centers is up 53.2%, or $18.44 to $53.11.

11:51 EST Gores Holdings III (Units) trading halted, volatility trading pause

11:13 EST Four Chinese military hackers indicted in 2017 Equifax breach - Attorney General William Barr announced the indictment of Chinese military hackers - specifically, four members of the Chinese People's Liberation Army - for breaking into the computer systems of the credit-reporting agency Equifax, and for stealing the sensitive personal information of nearly half of all American citizens, and also Equifax's intellectual property. "This was one of the largest data breaches in history. It came to light in the summer of 2017, when Equifax announced the theft. The scale of the theft was staggering. As alleged in the indictment, the hackers obtained the names, birth dates, and social security numbers of nearly 150 million Americans, and the driver's license numbers of at least 10 million Americans. This theft not only caused significant financial damage to Equifax, but invaded the privacy of many millions of Americans, and imposed substantial costs and burdens on them as they have had to take measures to protect against identity theft. As described in the indictment, the hackers broke into Equifax's network through a vulnerability in the company's dispute resolution website. Once in the network, the hackers spent weeks conducting reconnaissance, uploading malicious software, and stealing login credentials, all to set the stage to steal vast amounts of data from Equifax's systems. While doing this, the hackers also stole Equifax's trade secrets, embodied by the compiled data and complex database designs used to store the personal information. Those trade secrets were the product of decades of investment and hard work by the company... In addition to thefts of sensitive personal data, our cases reveal a pattern of state-sponsored computer intrusions and thefts by China targeting trade secrets and confidential business information: hacks by a group known as APT 10, which worked in association with the Chinese Ministry of State Security, or MSS, to target managed service providers and their clients worldwide across industries; hacks by MSS intelligence officers who sought to steal intellectual property related to turbofan engines by using both insiders and computer operations, and; hacks by PLA officers who targeted victims in the nuclear power, metals, and solar products industries for the economic benefit of Chinese companies." Reference Link

11:08 EST Loews CEO Tisch says stock 'looks cheap' - Loews (L) CEO Jim Tisch says he expects Loews Hotels to be strong growth engine for the parent company. Says remains "very bullish" on CNA (CNA), insurance industry. Comments taken from Q4 earnings conference call.

11:00 EST Starbucks expanding airport licensed business model with two new partners - Starbucks stated in a post to its corporate blog: "We recognize the importance of bringing the elevated Starbucks Experience to our customers as they move throughout their day. In airport locations, we specifically look to licensed business partners that bring the knowledge and capabilities to reach more air travelers...With our customers in mind, we are expanding our airport licensed business model, adding Paradies Lagardere and OTG, along with HMS Host, as operators of our airport locations across the U.S. We expect to work with other likeminded operators in this growing industry over time to meet increasing customer demand. Through these partnerships, we will grow our footprint in more U.S. airports and terminals, reaching more customers and laying the groundwork for future innovation." Reference Link

10:06 EST International Isotopes reports FDA approval of Sodium Iodide 1-131 ANDA - International Isotopes announced that it has received approval from the U.S. Food and Drug Administration for its SODIUM IODIDE I-131 pharmaceutical product. SODIUM IODIDE I-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and carcinoma of the thyroid. The American Cancer Society estimates more than fifty thousand adults in the United States are diagnosed with thyroid cancer each year. Steve T. Laflin, President and CEO of the company, said, "We are very pleased to have gained FDA approval of this important pharmaceutical product, which is the only FDA approved generic product of its type manufactured in the United States. INIS has long established itself as a reliable supplier of radiochemicals and we have earned a reputation for high quality products and excellent customer service. Extending our reach to provide FDA approved products is a logical extension of our current supply arrangements. INIS has several additional products at various stages of development in our pipeline. With the successful FDA approval of our first pharmaceutical product, we look forward to utilizing SODIUM IODIDE I-131 as a springboard to advance additional products we have under development. SODIUM IODIDE I-131 will be an important addition to the company's product offerings, and we anticipate launching commercial distribution in the very near future."

10:00 EST Consol Coal falls -9.6% - Consol Coal is down -9.6%, or -$1.01 to $9.52.

10:00 EST VelocityShares 3x Long Natural Gas ETN falls -10.2% - VelocityShares 3x Long Natural Gas ETN is down -10.2%, or -$4.58 to $40.23.

10:00 EST Edgewell Personal Care rises 20.8% - Edgewell Personal Care is up 20.8%, or $6.33 to $36.81.

09:56 EST Eagle Pharmaceuticals receives final FDA approval for PEMFEXY - Eagle Pharmaceuticals (EGRX) announced that it has received final approval from the U.S. FDA for its novel product, PEMFEXY, a branded alternative to ALIMTA. The conversion from tentative to a final approval follows the company's settlement agreement reached with Eli Lilly and Company (LLY) on December 13, 2019. This agreement provides for a release of all claims by the parties and allows for an initial entry of PEMFEXY into the market on February 1, 2022, and a subsequent uncapped entry on April 1, 2022.

09:47 EST VelocityShares 3x Long Natural Gas ETN falls -10.2% - VelocityShares 3x Long Natural Gas ETN is down -10.2%, or -$4.56 to $40.25.

09:47 EST Macerich rises 11.0% - Macerich is up 11.0%, or $2.58 to $25.94.

09:47 EST Taubman Centers rises 53.5% - Taubman Centers is up 53.5%, or $18.54 to $53.21.

09:16 EST New Pacific Metals reports summary of exploration on Silver Sand Project - New Pacific Metals Corp. reports a summary of exploration activities on its 100% owned Silver Sand Project, and a summary of acquisition and agreements with third parties on the properties surrounding its 100% owned Silver Sand Project. "Since acquired by New Pacific in 2017, Alcira has carried out extensive risk exploration drilling program on its 100% owned Silver Sand Project...From 2017 to the end of 2019, Alcira has completed 97,619.05m of drilling in 386 drill holes...New Pacific will continue to work with government of Bolivia, COMIBOL, co-operatives, local communities, and private sectors to invest more funds in Bolivia's mineral resource industry. While waiting for the MPC being ratified, approved, or re-worked, New Pacific will focus on defining an economic resource in its 100% owned Silver Sand Project," the company stated in part.

09:14 EST EVI Industries to acquire Commercial Laundry Equipment, terms undisclosed - EVI Industries announced that it executed a definitive purchase agreement to acquire substantially all the assets and certain liabilities of Richmond, Virginia based Commercial Laundry Equipment, or CLE, a distributor of on-premise and vended laundry products and a provider of related installation and maintenance services to the new and replacement markets of the commercial laundry industry. This acquisition expands EVI's sales and service presence in the Mid-Atlantic, which coincides with EVI's strategy to build distribution and service density in geographic markets through which it may provide additional products and services and improve customer service. Consistent with EVI's operating model, CLE will continue to operate under its existing name, with its existing people, and under the leadership of Tom Brittle, president of CLE. The transaction is expected to close upon the satisfaction of closing conditions. Terms of the acquisition were not disclosed. Consideration includes a combination of cash and EVI common stock.

09:08 EST INmune Bio awarded $500,000 grant for development of ALS treatment - INmune Bio announced that it has been awarded a $500,000 grant from The ALS Association. The grant will fund proof-of-concept studies for XPro1595, a novel therapy targeting innate immune dysfunction and chronic inflammation as a cause of Amyotrophic lateral sclerosis. The endowment was awarded through the Association's The Lawrence and Isabel Barnett Drug Development Program and will be allocated over two years.

09:07 EST Seanergy Maritime announces completion of IMO 2020 Compliance Plan - Seanergy Maritime Holdings announced the successful completion of its IMO 2020 compliance plan. As of the date of this release, the Company has retrofitted five Capesize vessels, or 50% of its owned fleet, with scrubbers. The costs of the scrubber program were borne by the vessels' charterers under long-term time charters which the Company entered into in 2018 and 2019, with the last of these charters commencing on schedule on December 19, 2019. All scrubber systems installed are open loop type, U-Type design, built by Hyundai Materials Corporation of S. Korea and have the capacity to comply with the stricter 0.1% sulphur fuel content limit applicable in the Environmentally Controlled Areas. The installations took place at Yiu Lian shipyard in Zhoushan, China. The costs of the acquisition and installation of the scrubbers, as well as the largest part of the associated off-hires incurred in 2019, were borne by the charterers. The settlement of the relevant costs by the charterers was made either in the form of immediate reimbursement of the expenses incurred or fixed premiums over the daily index-linked charter hire. The charterers consist of global commodities traders and utilities companies. The duration of the underlying time charters ranges between three and five years at rates based on the Baltic Capesize Index. In addition to the daily hire, there is a profit-sharing element based on the fuel spread. The total investment by the charterers in Seanergy's vessels exceeded $14M. During the second half of 2019, the Company procured sufficient quantity of MGO at competitive pricing in order to cover the needs of the five non-scrubber fitted vessels for the majority of the first quarter of 2020. The proactive procurement of 0.1% sulphur content fuel oil ensured the seamless compliance of the Company's non-scrubber fitted vessels with the IMO 2020 regulation while providing for a natural hedge against the adverse movements in the price of compliant fuel oils.

09:05 EST GoDaddy appoints Leah Sweet to board of directors - GoDaddy (GDDY) announced that Leah Sweet, senior vice president at PayPal (PYPL), has been appointed to its board of directors. Prior to PayPal, Sweet was a vice president at CA Technologies.

09:05 EST Liberty Global extends partnership with Netflix across European footprint - Liberty Global (LBTYA, LBTYK) announced a multi-year deal with Netflix (NFLX) that will continue to offer 11M video customers in Europe convenient access to the Netflix service, including some of today's most popular and award-winning series, movies and original content, such as The Irishman, Sex Education and The Witcher. The partnership follows Liberty Global's commitment to leverage its next-generation Gigabit speed broadband networks to provide its customers with their favorite streaming content, alongside world-class broadcast and on demand programming on the main TV screens in the home, in a truly seamless and flexible viewer experience.

09:03 EST Aethlon Medical trading halted by SEC - On February 7, the SEC issued an Order of Suspension of Trading, temporarily suspending trading in Aethlon Medical stock for a period of ten days. The SEC Order stated that the suspension was due to concerns regarding the accuracy and adequacy of information in the marketplace that appeared to be disseminated by third party promotors and recent and unusual market activity since at least January 22. Aethlon is aware that certain third party promoters may have made claims about the potential efficacy of its products with respect to coronavirus. The company neither solicited, had advance knowledge of, nor played any role in the preparation of such reports.

09:00 EST Diplomat Pharmacy trading halted, news dissemination

08:44 EST Avis Budget appoints Bernardo Hees as chairman of the board - Avis Budget Group announced that Bernardo Hees has been appointed to the Company's Board of Directors and named Independent Chairman of the Board and Chair of the Board's Executive Committee, effective immediately. Over the last 15 years, Mr. Hees has served as CEO of The Kraft Heinz Company, Burger King Worldwide Holdings, Inc., and America Latina Logistica. He succeeds Independent Chairman Leonard Coleman, who will continue as a Director. Hees is making a personal investment of $15M in Avis shares to align his interests with those of all shareholders. The shares will be issued at the closing price of Avis common stock on February 7, 2020.

08:40 EST Wrap Technologies receives purchase orders for 200 BolaWraps, 2,000 cartridges - Wrap Technologies announced it has received international purchase orders for 200 BolaWraps and 2,000 cartridges and accessories. The purchasing police agency placed the orders after demonstrations and trainings completed late last year. Wrap also received an initial order in January from a new Asian country to commence demonstrations and trials of BolaWrap. The company expects to recognize revenues from the orders during Q1. During the month of January, Wrap also demonstrated BolaWrap in two additional countries in Asia. The company has delivered product to 22 different countries and signed 16 international distributors covering 26 countries in the last 10 months.

08:37 EST Millendo Therapeutics names Dr. Christophe Arbet-Engels as Chief Medical Officer - Millendo Therapeutics announced that Christophe Arbet-Engels, MD, PhD, has joined the company as Chief Medical Officer. The company also announced that it expects to report topline results from the Phase 2b portion of its pivotal Phase 2b/3 clinical trial for livoletide in patients with Prader-Willi syndrome, or PWS, called ZEPHYR, early in the second quarter of 2020. Dr. Arbet-Engels joins Millendo from Poxel Pharmaceuticals where he was Chief Medical Officer.

08:36 EST Gilead announces FDA acceptance of KTE-X19 BLA - Kite, a Gilead company, announced that the FDA has accepted the biologics license application, or BLA, and granted priority review designation for KTE-X19, an investigational chimeric antigen receptor, or CAR T, cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, or MCL. The BLA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which showed that 93% of patients responded to a single infusion of KTE-X19, including 67% of patients achieving a complete response, as assessed by an Independent Radiologic Review Committee. In the safety analysis, Grade 3 or higher cytokine release syndrome, or CRS, and neurologic events were seen in 15% and 31% of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented during an oral session at the 61st American Society of Hematology, or ASH. The Prescription Drug User Fee Act, or target action date, is August 10.

08:35 EST Granite Construction appoints Kyle Larkin as COO - Granite Construction announced that effective today, Kyle Larkin has been appointed executive vice president and COO. Larkin will be responsible for overseeing the day-to-day operations of the company and will continue to be a member of the executive committee reporting directly to James H. Roberts, president and chief executive officer of Granite. Most recently, in 2019, Larkin was named the senior vice president and manager of the Construction Materials Operations, which is comprised of the California Group, the Northwest Group, the Infrastructure Services Group, and all vertically-integrated materials facilities.

08:34 EST Myovant Sciences expects to submit NDA for relugolix tablet in 2Q20 - In November 2019, Myovant announced that the Phase 3 HERO study evaluating the safety and efficacy of once-daily, oral relugolix monotherapy over 48 weeks in 934 men with advanced prostate cancer met its primary efficacy endpoint with a 96.7% response rate and all tested key secondary endpoints, while demonstrating 54% fewer major cardiovascular events as compared with leuprolide injections administered every three months. Myovant anticipates submitting its NDA for relugolix monotherapy tablet for men with advanced prostate cancer in the second quarter of calendar year 2020.

08:31 EST Plantronics names Robert Hagerty as interim CEO, succeeding Joe Burton - Plantronics announced that Robert Hagerty, Chairman of the Poly Board of Directors, has been appointed Interim CEO, effective immediately. This appointment follows Joe Burton's decision to step down as President and CEO by mutual agreement with the Board. Burton will work closely with Hagerty to ensure an orderly transition of responsibilities. Hagerty will continue in his role as Chairman and Marv Tseu, Vice Chairman of the Board, will serve as the company's lead independent director while Hagerty serves in the interim role.

08:25 EST RigNet signs long-term agreement with Northern Offshore - RigNet announced that it has signed a long-term agreement with Northern Offshore, a global offshore drilling company, to provide various services to their fleet of rigs in the Middle East. Under this agreement, RigNet will provide several solutions including VSAT Managed Communications Services, CrewFlix Video on Demand, CrewHotspot internet, and Enhanced Cyber Services. RigNet is providing an advanced VSAT solution with voice and high-speed data communications as well as 24/7 remote network monitoring and technical support. This will be combined with RigNet's ECS offering, an improved data and system security solution with real-time threat detection, as well as an advanced conditional access system tailored for 3rd-party partners on offshore rigs. In addition, RigNet is also providing crew information and entertainment services from its CrewConnect portfolio, including CrewFlix, RigNet's video-on-demand service and Crew Hotspot, a dedicated crew internet access point. The CrewConnect portfolio provides services for improved crew morale in remote locations, enhancing operational efficiency through reduced employee turnover and increased productivity.

08:20 EST Better Choice Company to form animal health JV with cbdMD - Better Choice Company (BTTR) announced the execution of a non binding letter of intent to form a joint venture with cbdMD, Inc. (YCBD). Subject to the negotiation and execution of definitive agreements both parties intend to contribute certain CBD animal health related assets, including brands, CBD supply, logistics, service agreements, intellectual property, back office support and other assets with the mutual goal of expanding their respective hemp derived CBD pet brands, in exchange for 50% ownership in the newly formed JV. Initially, the JV will be focused on launching "Halo Hemp", "powered by cbdMD", which will be manufactured by Better Choice utilizing cbdMD's CBD supply. Both parties will leverage their sales teams, marketing capabilities, online presence, and distribution channels to maximize the economies of scale of the partnership.

08:17 EST nVent Electric announces acquisition of WBT business - nVent Electric announced the acquisition of substantially all of the assets of WBT LLC, a U.S.-based manufacturer of cable tray, a business that will become part of nVent's Electrical & Fastening Solutions segment, marketed as part of the nVent CADDY product line. An innovative and customer-focused business, Centralia, IL-based WBT manufactures high-quality cable tray, and has approximately 40 employees supporting manufacturing in Centralia and Chandler, AZ.

08:15 EST ADT Inc., HHHunt announce partnership for smart home technology - ADT announced a new flagship partnership with HHHunt, a diversified leader in real estate development, to install smart home and property automation technology into new and existing HHHunt multifamily and student housing communities. ADT adds HHHunt to its growing list of prominent real estate partners enhancing their communities with smart home solutions. ADT will work with HHHunt to install more than 7,700 apartment homes in 19 communities across four states with smart hubs, smart locks, smart thermostats and integrate into industry-leading property management software. Of these residences, more than 1,300 will be student housing apartment homes, reflecting a growing demand for smart home amenities for student living.

08:14 EST NV5 Global awarded $34M LNG contract - NV5 Global announced that it has been awarded a $34M engineering, procurement, and construction contract by a prominent Eastern US natural gas company for a liquefied natural gas facility liquefaction system upgrade. Design has begun on the new facility, and the project is expected to be completed in approximately 18 months. Liquefaction systems are used in the natural gas industry to convert natural gas from a vapor phase to a liquid phase, allowing for more efficient storage and transportation. The new liquefier will replace an older system to increase capacity and improve reliability, safety, and ease of operation.

08:11 EST Western Forest, USW reach tenative collective agreement - Western Forest Products announced that the Company and the United Steelworkers Local 1-1937 have agreed to the terms of a tentative collective agreement. The tentative agreement is subject to a ratification vote by USW membership. The USW bargaining committee has advised that they will be recommending that its members accept this agreement

08:08 EST Xerox increases offer price for HP Inc. to $24.00 per share - Xerox (XRX) announced its intention to launch a tender offer on or around March 2 for all of the outstanding shares of common stock of HP Inc. (HPQ) at a price of $24.00 per share, which will be comprised of $18.40 in cash and 0.149 Xerox shares for each HP share. The tender offer will not be subject to any conditions related to financing or due diligence. Xerox has met, in some cases multiple times, with many of HP's largest stockholders. These stockholders consistently state that they want the enhanced returns, improved growth prospects and best-in-class human capital that will result from a combination of Xerox and HP. The tender offer announced today will enable these stockholders to accept Xerox's compelling offer despite HP's consistent refusal to pursue the opportunity. The value created by the synergies realized in a combination of Xerox and HP is incremental to any value that HP can create by revising its strategic plan or dramatically changing its capital allocation policy to incorporate additional share repurchases. Xerox's offer provides HP stockholders with both significant, immediate cash value, and meaningful upside via equity ownership in the combined company. The headline offer price of $24.00 per share represents a 41% premium to HP's unaffected 30-day volume weighted average trading price of $17.00. The implied offer value of ~$33 per share2 represents a 94% premium to HP's unaffected 30-day volume weighted average trading price of $17.00.

08:07 EST Aptorum Group announces update on repurposed drug candidate SACT-1 - Aptorum Group announced data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare type of childhood cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group plans to leverage the 505 pathway and submit an IND submission with the FDA for SACT-1 in H2 2020. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACTTM drug discovery platform, which employs a systematic approach to identify, repurpose and develop existing approved drugs against a currently identified universe of 7000+ orphan diseases. Through this platform, Aptorum Group intends to accelerate and fast track repurposed drug candidates, which usually have well established human safety and toxicity profiles and data, through the development and clinical phases in order to address the rapidly growing market of orphan diseases. Aptorum Group aims to screen a number of orphan disease areas including, but not limited to, oncology, autoimmune, metabolic and genetic diseases. Through the Smart-ACTTM platform, Aptorum has identified potential efficacy for and develops SACT-1 for the treatment of neuroblastoma, being an entirely new therapeutic area from its approved indication. In recent studies, SACT-1 has been shown to be effective against numerous neuroblastoma cell lines, of which 2 are MYCN-amplified cells, which represent the high-risk neuroblastoma patient group. In addition, by using a combination index as a quantitative measure of the extent of drug interaction, Aptorum Group has seen a high and robust synergism between SACT-1 and traditional chemotherapy in vitro, indicating a potential efficacy enhancement/dose reduction of the chemotherapy. In addition, in our recent study, the maximum tolerable dose of SACT-1 in a rodent model was determined to be higher than 400mg/kg. Compared with the MTD of standard chemotherapy such as paclitaxel and cisplatin, the safety profile of SACT-1 appears to be "impressive". The reformulation of SACT-1 is a pediatric formulation to better address the needs of neuroblastoma patients who are exclusively children younger than five. Based on our internal observations of pre-existing information from approved products, SACT-1 also exhibits a well-established safety profile: at 150mg/day, the death rate was 0% in prior clinical studies with no dosage related adverse events.

08:06 EST Xerox increases offer price for HP Inc. to $24.00 per share

08:06 EST Daseke names Chris Easter as CEO - Daseke announced that on February 7, 2020, its Board of Directors appointed Chris Easter, former interim CEO, as permanent CEO. In addition to his role as CEO, Chris Easter has also become a member of the Board of Directors.

08:03 EST Del Taco appoints Tim Hackbardt as CMO - Del Taco announced that Tim Hackbardt has been appointed CMO. Hackbardt is a restaurant industry veteran with over 27 years of experience and has led or advised numerous restaurant chains as a marketing executive and brand consultant across the quick-service, fast-casual, family dining, casual and polished-casual categories. Hackbardt's experience also includes four years leading marketing for Del Taco.

08:01 EST Jack Henry raises quarterly dividend 8% to 43c per share - Payable on March 19 to stockholders of record as of March 2.

07:50 EST Biohaven down 16% after Phase 3 study of troriluzole misses primary endpoint - In pre-market trading, shares are down 16% to $42.99.

07:42 EST Axon partners with Bureau of Alcohol, Tobacco, Firearms and Explosives - Axon announced that the Bureau of Alcohol, Tobacco, Firearms and Explosives will equip agents and investigators with the Axon Investigator suite of solutions, which includes Axon Body 3 cameras, backed by Axon Evidence, a FedRamp-Authorized cloud-based digital evidence management solution available to federal law enforcement. Axon will support the ATF pilot initiative with a 12-month indefinite delivery, indefinite quantity contract. This order was received in the fourth quarter of 2019 and will ship in multiple phases throughout 2020.

07:39 EST Seeco Holding reaches agreement with Lanvin to launch e-flagship store - Secoo Holding officially announced that Lanvin, "one of the oldest French fashion houses," launched its online flagship store on Secoo platform on February 10th. For the launch of the Lanvin e-flagship store, Secoo also produced an original Lanvin content video for Secoo platform and for the use of both Secoo's and Lanvin's social media channels introducing Lanvin's spirit to Secoo's 30M+ premium members.

07:37 EST Intellia presents data from engineered cell therapy, in vivo programs - Intellia Therapeutics is presenting new data from two of its development programs at Keystone Symposia's Engineering the Genome Conference, a joint meeting with the Emerging Cellular Therapies: Cancer and Beyond Conference, taking place Feb. 8-12, 2020, in Banff, Canada. Intellia researchers are presenting data in support of the company's lead engineered cell therapy development candidate, NTLA-5001 for the treatment of the hematological cancer, acute myeloid leukemia. Intellia also is sharing preclinical results for its hereditary angioedema program, which is Intellia's third CRISPR/Cas9 development program, announced in January 2020. NTLA-5001, which is Intellia's first engineered T cell therapy development candidate and is wholly owned, utilizes a T cell receptor-directed approach to target the Wilms' Tumor 1 intracellular antigen for the treatment of AML. The company's WT1-TCR T cell approach aims to develop a broadly applicable treatment for AML patients, regardless of mutational background of a patient's leukemia. The company is presenting data demonstrating that the selection of a natural, high-affinity TCR, in combination with CRISPR-enabled engineering and targeted insertion, results in an engineered T cell capable of specific and potent killing of primary AML blasts. The data being presented at the Keystone conference substantiate the advantages that a homogeneous T cell product developed through CRISPR engineering, like NTLA-5001, may have over traditional T cell engineering approaches. In particular, traditional T cell engineering methods typically result in a T cell product that carries two different TCRs, one endogenous and one transferred, which can pair in various combinations of alpha and beta chains and form mixed TCRs with unknown specificities. Intellia researchers are sharing today that the precise replacement of the endogenous TCR with the transgenic TCR resulted in T cells with improved tgTCR expression levels and in 95% of edited T cells carrying exclusively the desired pairs of the tgTCR alpha and beta chains. This therapeutic TCR profile is expected to yield improved T cell product homogeneity, as researchers showed that Intellia's T cell editing approach results in superior function of the engineered T cells toward WT1-positive targets in vitro. This therapeutic TCR profile is also expected to result in lower reactivity against unwanted targets on normal tissues that could lead to toxicities, including graft-versus-host disease. Researchers identified that the selected lead WT1 TCR exhibits high avidity to its target epitope and shows tight epitope specificity. Being a natural TCR isolated from a healthy donor, it may have a lower cross-reactivity risk than many affinity-matured TCRs. Cells engineered with Intellia's lead WT1 TCR also demonstrated no detectable cytotoxicity toward bone marrow CD34+ cells, which express WT1 at low levels. This is an advantage over current CAR-T cell approaches targeting CD33 or CD123 in AML, which have been shown to induce severe bone marrow toxicity. Furthermore, the data demonstrate that specific and potent killing of WT1-positive primary AML blasts result from T cells expressing Intellia's lead WT1 TCR when cocultured in vitro. This outcome was observed across multiple patient samples that harbor the frequent HLA-A*02:01 allele and that express different WT1 levels as well as AML characteristics. These data validate that the epitope targeted by the lead WT1 TCR, which is distinct from a previously evaluated RMF epitope, is presented efficiently and broadly by AML tumor cells that carry the correct human leukocyte antigen restriction. Intellia's lead WT1 TCR also has the potential to target WT1-positive solid tumors, such as ovarian cancer, glioblastoma, lung cancer and mesothelioma. The company plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration in the first half of 2021 for NTLA-5001 for the treatment of AML. Researchers presented yesterday at the Keystone conference the company's first dataset in support of Intellia's development program for HAE. HAE is a rare genetic disorder characterized by recurring and unpredictable severe swelling attacks in various parts of the body, and is significantly debilitating or even fatal in certain cases. The disease is caused by increased levels of the bradykinin protein. Most patients with HAE have a C1 esterase inhibitor protein deficiency, which normally prevents the unregulated release and buildup of bradykinin. Intellia's HAE treatment hypothesis involves knocking out the kallikrein B1 gene to reduce kallikrein activity, which is involved in the biological pathway for release of bradykinin. Intellia expects this reduction to correlate with a decrease in bradykinin activity, thus, preventing the activation of endothelial cells that causes vascular leakage and angioedema in HAE patients. The data presented at the Keystone conference showed that the knockout of KLKB1 produces in non-human primates a 90% reduction in kallikrein activity, a level that translates to a therapeutically meaningful impact on HAE attack rates. This kallikrein activity reduction was sustained for at least five months in an ongoing NHP study, in a highly reproducible manner observed across both rodent and NHP studies. Similar to its lead in vivo program, for the treatment of transthyretin amyloidosis, Intellia's potential HAE therapy utilizes the company's modular non-viral lipid nanoparticle system to deliver CRISPR/Cas9. Intellia's proprietary LNP-based delivery system includes two basic components: Cas9 messenger RNA and a guide RNA. The gRNA is the only variable portion of the LNP delivery system and is the sole component that needs to be changed from the LNP-based delivery system that forms the foundation of NTLA-2001, Intellia's development candidate for the treatment of ATTR for which the company intends to submit an IND application in mid-2020. Intellia continues to evaluate several potential guide RNAs and expects to nominate a development candidate for HAE in the first half of 2020. Intellia's KLKB1 HAE program is subject to an option by Regeneron to enter into a Co/Co agreement, in which Intellia would remain the lead party.

07:34 EST Wolters Kluwer completes acquisition of CGE Risk Management Solutions - Wolters Kluwer announces that it has completed the acquisition of CGE Risk Management Solutions B.V., as originally announced on January 16, 2020.

07:33 EST GeoPark renews share repurchase plan, declares special stock dividend - GeoPark announced that its board has approved the renewal of a program to repurchase up to 10% of its shares outstanding or approximately 5.93M shares and the declaration of a special stock dividend of 0.004 shares per share. The repurchase program will begin on February 11 and will expire on December 31. GeoPark's board declared a special stock dividend of 0.004 shares per share to be paid on March 11 to the shareholders of record at the close of business on February 25. The company will pay cash in lieu of any fractional shares. The special stock dividend complements the renewal of the share repurchase program and the existing quarterly cash dividend policy of $2.5M.

07:29 EST Revive Therapeutics announces agreement, investment in Red Light Holland - Revive Therapeutics announced that it has entered into a supply and collaboration agreement with Red Light Holland Financing, an arm's length party. Pursuant to the Agreement Red Light will sell to Revive a consistent strain of truffles for the sole purpose of Revive undertaking research and development on the suitability and implementation of its novel cannabinoid delivery technology with respect to the truffles and its extracts. Red Light has also agreed to, upon request, provide Revive with any information, studies, papers and other information it may have pertaining to the truffles which may be deemed to be beneficial to Revive for undertaking the research and development. In addition, as a condition of the Agreement, Revive has agreed to subscribe for 2,500,000 subscription receipts of Red Light at a price of $0.06 per Subscription Receipt for an aggregate consideration of $150,000. Each Subscription Receipt shall entitle Revive, upon conversion and with any additional consideration, to acquire one common share in the capital of Red Light. In consideration for the Subscription Receipts, Revive will issue to Red Light an aggregate of 3,000,000 common shares in the capital of Revive at a price of $0.05 per share for aggregate consideration of $150,000.

07:27 EST Taubman Centers trading resumes

07:26 EST Biohaven Pharmaceutical: Phase 3 study of troriluzole misses primary endpoint - Biohaven Pharmaceutical reported negative topline results from its Phase 3 clinical trial evaluating troriluzole compared to placebo for the treatment of patients with Generalized Anxiety Disorder. This eight-week trial randomized 402 adult patients equally at more than 45 centers in the United States. In this trial, troriluzole monotherapy at 100mg twice daily did not differentiate from placebo on the primary endpoint of the mean change from baseline on the Hamilton Anxiety Rating Scale after eight weeks of treatment. Vlad Coric, M.D., CEO of Biohaven, "While these efficacy results were disappointing and do not support continued development of troriliuzole as a monotherapy in GAD, we have multiple ongoing studies evaluating troriluzole in other disease indications and with different dosing paradigms. Since it is often difficult to predict clinical outcomes from preclinical and early clinical proof of concept studies, our strategy has been to test troriluzole in four distinct disorders where glutamate has been implicated in the underlying pathophysiology of the illnesses. We eagerly await topline data from our adjunctive therapy trial in OCD, and our symptomatic treatment trials in Alzheimer's disease and Spinocerebellar Ataxia. We thank the patients and clinical investigators who participated in the GAD program and sincerely appreciate all that they have done to see this study through completion."

07:22 EST Mereo BioPharma enters $5M convertible equity financing with Novartis - Mereo BioPharma Group (MREO) announced that it has entered into a $5 million convertible equity financing with Novartis Pharma (NVS) and concurrently entered into a Securities Purchase Agreement to issue up to $28 million of the Company's ordinary shares exchangeable for American Depositary Shares, including a $3 million initial purchase, with Aspire Capital Fund, a Chicago-based institutional investor. Proceeds from these transactions are intended to be used by Mereo for general corporate purposes, including clinical trial activity and working capital. Under the terms of the convertible equity financing, Novartis will purchase $5 million in a convertible loan note. The Loan Note is convertible at any time at a fixed price of GBP 0.265 per ordinary share. The maturity of the Loan Note is three years from issuance, and it bears an interest rate of 6% per annum. In connection with the Loan Note issuance, the Company also issued a warrant instrument to Novartis to purchase up to 1,449,614 of the Company's ordinary shares, which are exercisable at an exercise price of GBP 0.265 per ordinary share at any time before the close of business on February 10, 2025. The Loan Note will be subordinate to Mereo's outstanding loan agreement with Silicon Valley Bank and Kreos Capital.

07:20 EST Simon Property CEO sees Taubman Centers deal 'immediately accretive' to FFO - Simon (SPG) Chairman of the Board, CEO and President David Simon stated, "We are very pleased to announce this transaction, which will be immediately accretive to Simon's FFO. By joining together, we will enhance the ability of TRG to invest in innovative retail environments that create exciting shopping and entertainment experiences for consumers, immersive opportunities for retailers, and substantial new job prospects for local communities. I look forward to partnering with Bobby and the TRG executive team in this exciting new joint venture." Myron Ullman, Lead Director of the Taubman (TCO) Board of Directors and Chairman of the Special Committee of the Taubman Board of Directors, added, "The Taubman Board of Directors has always been focused on maximizing shareholder value. With this transaction, we will deliver a significant, immediate cash premium to shareholders. The Special Committee of the Board unanimously believes that this transaction with Simon is a great outcome for all of our stakeholders."

07:18 EST Simon Property to acquire Taubman Centers for $52.50 per share in cash - Simon Property Group (SPG) and Taubman Centers (TCO) announced that they have entered into a definitive agreement under which Simon will acquire an 80% ownership interest in The Taubman Realty Group Limited Partnership. Simon, through its operating partnership, Simon Property Group, L.P., will acquire all of Taubman common stock for $52.50 per share in cash and the Taubman family will sell approximately one-third of its ownership interest at the transaction price and remain a 20% partner in TRG. The transaction has been unanimously recommended by a Special Committee of independent directors of Taubman and approved unanimously by the Boards of Directors of both companies. Simon expects to fund the total required cash consideration of approximately $3.6B with existing liquidity. Required approvals for the transaction include: (i) two-thirds of the outstanding Taubman voting stock and (ii) a majority of the outstanding Taubman voting stock not held by the Taubman family. The Taubman family, which represents approximately 29% of outstanding Taubman voting stock, has agreed to vote in favor of the transaction. The transaction is also subject to customary closing conditions and is expected to close in mid-2020.

07:16 EST Trevena resubmits NDA for Oliceridine - Trevena announced that it has resubmitted its New Drug Application to the U.S. Food and Drug Administration for IV oliceridine, the Company's lead investigational product for the management of moderate-to-severe acute pain. The Company anticipates a six-month review period by FDA. The NDA for oliceridine was resubmitted based on the outcome and final minutes of a Type A meeting with FDA, which was conducted to obtain clarity on their Complete Response Letter. The resubmission package included data from the multi-dose healthy volunteer QT study, nonclinical data that confirmed levels of an inactive metabolite, and drug product validation reports. The resubmission package also specified a maximum daily dose of 27 mg, as previously acknowledged by FDA in the Type A meeting minutes. No efficacy data or additional comparative data versus IV morphine were requested as part of the CRL.

07:15 EST Simon Property to acquire Taubman Centers for $52.50 per share in cash

07:13 EST Allergan sees two 'significant launches' in next twelve months - Allergan expects two significant launches in the next twelve months: FDA action is expected in the first half of 2020 on Allergan's NDA for Bimatoprost Sustained-Release, a biodegradable implant for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Launch is expected to follow in the first half of 2020. The FDA is currently reviewing a Biologics License Application for Abicipar pegol, a novel, investigational DARPin therapy, in patients with neovascular age-related macular degeneration. The FDA is expected to take action on the BLA in mid-2020, with launch expected to follow. The European Medicines Agency is also reviewing a Marketing Authorisation Application for Abicipar in patients with nAMD. A decision from the European Commission is expected in the second half of 2020.

07:11 EST Acasti Pharma announces investigation into Phase 3 TRILOGY 1 results - Acasti Pharma announced that a detailed examination of the Phase 3 TRILOGY 1 results for CaPre is underway, including specific clinical site audits and an audit of the central testing laboratory. As previously reported, the Company noted a highly unusual placebo response in its topline triglyceride reduction primary endpoint, far greater than seen in any prior omega-3 triglyceride lowering trials, with 5 sites out of the total 54 enrolling sites disproportionately contributing to this placebo response. These sites accounted for about 36% of the 242 patients enrolled in the TRILOGY 1 study. By comparison, TRILOGY 2 was conducted at 71 sites in Canada, Mexico and the United States that enrolled a total of 278 patients. The 5 sites also participated in TRILOGY 2, however these sites accounted for only 12% of the total patients, with the majority of these patients coming from only 3 sites. Despite monitoring activities conducted throughout the TRILOGY 1 trial to ensure adherence to the protocol and identify protocol violations, the Company has subsequently identified some unexpected and inconsistent findings that it believes may have negatively contributed to the overall topline results. These findings are now being further explored via a comprehensive and rigorous review of data and patient medical records by an independent team of auditors. To support this effort, the Company, its independent Clinical Research Organization that conducted the TRILOGY studies, its principal investigator Dr. Mozaffarian, and other clinical and regulatory advisors, are conducting a thorough review of all data and records from patients taking both CaPre and placebo. This assessment is well underway, and the Company has also determined that a thorough investigation of the data must be completed and reviewed with the FDA, before the Company can report the findings from TRILOGY 1 and the implications for TRILOGY 2. Consequently, the Company intends to request a meeting with the FDA to discuss the TRILOGY 1 data, and will seek their guidance about how to conduct the analysis of the TRILOGY 2 data prior to unblinding TRILOGY 2. The Company continues to remain blinded to the TRILOGY 2 data. Upon submission of the meeting request, which is expected to be sent to the FDA in calendar Q2, 2020, the FDA will have 75 days to review the findings and provide feedback and guidance. Given the need to complete the audit and review of the TRILOGY 1 data, and obtain FDA feedback, the Company now anticipates the unblinding of the topline results for TRILOGY 2 sometime in calendar Q3 of 2020. Acasti will provide further guidance as to the timing of reporting TRILOGY 2 data based on progress of the audits and feedback from the FDA. Accordingly, key secondary and exploratory endpoints from both TRILOGY 1 and TRILOGY 2 studies, would now be expected as soon as possible after the unblinding of TRILOGY 2 results. If the interpretation of the analyses produced as an outcome of the audits and post-hoc data review are supported by the FDA, and if TRILOGY 2 achieves statistical significance, Acasti believes it may still have a viable path forward to file an NDA for CaPre.

07:09 EST Akorn confirms negotiations with certain of its lenders are ongoing - Akorn confirmed that negotiations with certain of its lenders are ongoing following the expiration of its standstill agreement on February 7. Akorn continues to evaluate strategic alternatives to address the company's litigation-related liabilities and position Akorn for long-term success.

07:09 EST vTv Therapeutics says TTP399 achieves primary objective in Phase 2 study - vTv Therapeutics announced results from Part 2 of the Phase 2 Simplici-T1 trial assessing TTP399 as an oral adjunctive therapy to insulin in adults with type 1 diabetes. TTP399 is a novel, liver-selective glucokinase activator taken once a day. The 12-week trial investigated the efficacy and safety of 800 mg of TTP399 compared with placebo in 85 people with type 1 diabetes on optimized insulin therapy. The study was conducted with support from JDRF International, the leading provider of T1D research funding globally. The trial successfully achieved its primary objective analyzed using two statistical approaches to evaluating the effect of TTP399. The primary statistical analysis evaluated the effect on HbA1c regardless of treatment adherence or notable changes in insulin administration. Under the primary statistical analysis, the trial achieved its primary objective by demonstrating statistically significant improvements in HbA1c for TTP399 compared to placebo at week 1. TTP399 was well tolerated with similar incidences of treatment-emergent adverse events overall and by system organ class in both treatment groups. The study had no report of diabetic ketoacidosis in either treatment group. There was no incidence of severe hypoglycemia in the treated group and one incident in the placebo group. Patients taking TTP399 experienced fewer symptomatic hypoglycemic episodes: two subjects taking TTP399 reported at least one event compared to eight subjects taking placebo. To eliminate the possibility that the reduction in HbA1c was driven by the administration of excess insulin, a second estimand analysis was performed.1 Based upon this analysis, people treated with TTP399 achieved a statistically-significant placebo-subtracted reduction in HbA1c of 0.32%. Patients taking TTP399 experienced a 0.21% reduction in HbA1c, while patients taking placebo experienced a 0.11% increase in HbA1c, from a mean study baseline HbA1c of 7.6% following a multi-week insulin optimization period prior to the administration of study treatment. Daily Time in Range was improved by approximately two hours in patients treated with TTP399 relative to placebo. TTP399 treatment reduced the total daily mealtime bolus insulin dose by 11% relative to baseline whereas the placebo-treated group experienced a 3% decrease relative to baseline. Despite advances in insulin and its administration, people with T1D continue to have difficulty achieving optimal glucose control, warranting the need for adjunctive therapies. TTP399 selectively activates glucokinase, a key regulator of glucose metabolism, in the liver. This activation has been shown to increase glucose utilization, which in turn lowers blood glucose. Simplici-T1 is the first study to test activation of GK in patients with T1D, evaluating daily oral TTP399 as an adjunct to insulin therapy.

07:06 EST Just Energy sees FY20 Base EBITDA $150M-$170M - The company said, "Just Energy continues to focus on enhancing its customer base by adding new, high-quality customers and providing a variety of energy management solutions to its customer base to drive customer loyalty and improved profitability. The impact of cost cutting initiatives implemented to date is evident in the third quarter results and Just Energy expects this progress to continue as additional changes are made. The Company is on pace to realize approximately $60 million in administrative, selling and capital cost savings in fiscal year 2020 and will continue to review its operations for additional ways to improve efficiencies and lower its cost structure. The recent sale of non-core operations and exiting of lower potential markets demonstrates Just Energy's commitment to focus on its higher margin North American operations. The sale of the U.K. and Ireland operations is now complete, as is the sale of the Company's Georgia assets, and Just Energy continues to actively market its remaining non-core operations. The previously announced strategic review has provided valuable insights into how best to unlock additional value from the business through a comprehensive review of capital expenditures, streamlining the organization and further refinement of the geographic footprint via disposition of non-core businesses. In addition to identifying cost saving actions and refinement of the Company's geographic footprint, the Company has been active in discussions with respect to strategic transaction opportunities. While no decisions related to any strategic alternative have been reached at this time, the strategic review process is advancing down a path consistent with the Board's goal of an outcome that is in the best interests of Just Energy and its stakeholders. Just Energy anticipates announcing a decision on the strategic review by June 30, 2020. In the interim, the Company does not intend to comment further with respect to the strategic review unless and until it determines that additional disclosure is appropriate in the circumstances and in accordance with the requirements of applicable securities laws. The Company cautions that there is no assurance that a transaction will result from the strategic review. As a result of lower than expected Base EBITDA and free cash flow in the third quarter of fiscal 2020 and lower fiscal year to date customer additions, management revised its full year fiscal 2020 Base EBITDA guidance from continuing operations to between $150 million to $170 million, from $180 million to $200 million, and decreased fiscal year 2020 free cash flow guidance to between $0 million to $20 million, from $50 million to $70 million. Free cash flow is defined as cash flow from operating activities minus cash flow from investing activities."

07:04 EST Just Energy expects strategic review decision no later than June 30 - The Company's previously announced strategic review remains active and is advancing towards the Board's goal of an outcome in the best interests of Just Energy and its stakeholders. In addition to identifying cost saving actions and refinement of the Company's geographic footprint, the Company has been active in discussions with respect to strategic transaction opportunities. Just Energy anticipates announcing a decision on the strategic review by June 30, 2020. However, there is no assurance that a transaction will result from the strategic review.

07:02 EST Taubman Centers trading halted, news pending

06:32 EST OneSmart appoints Jinshu Ke as Chief Education Officer - OneSmart announced that it has appointed Jinshu Ke as Chief Education Officer, effective February 1. He will report to Mr. Xi Zhang, Chairman and CEO. Ke has served as Senior Vice President of OneSmart since August 2017.

06:25 EST Edgewell Personal Care terminates merger agreement with Harry's

06:08 EST I Squared Capital acquires interest in OCENSA pipeline in Colombia - I Squared Capital, through its ISQ Global Infrastructure Fund II, has acquired an indirect equity interest in Oleoducto Central, S.A. from Advent International. OCENSA operates the largest crude oil pipeline in Colombia with a capacity of 680,000 barrels per day and transports approximately 75% of the oil produced in the country. The company began operations in 1998 and is controlled and operated by CENIT Transporte y Logistica de Hidrocarburos S.A.S., a wholly owned midstream-dedicated subsidiary of Ecopetrol. The 848-kilometer pipeline is mostly underground and originates in the Llanos Basin, Colombia's most prolific oil producing region, and ends at a wholly owned export terminal in the port of Covenas, the main oil export port in the country. Especially well positioned to transport heavy crudes, OCENSA is a highly cost-effective and reliable option for producers in the Llanos Basin.

06:07 EST New Fortress Energy signs long-term LNG supply agreement - New Fortress Energy announced that it has signed a long-term supply agreement for the purchase of 27.5M MMBtu per annum of liquefied natural gas, or approximately 8 cargoes a year, at a price indexed to Henry Hub through January 2030. This agreement will support the continued growth of New Fortress' customer base in international markets as the company develops LNG terminals and natural gas infrastructure.

05:51 EST NIO Inc. reports Jan. deliveries down 11.5% to 1,598 vehicles - NIO Inc. provided its January 2020 delivery results. NIO delivered 1,598 vehicles in January, 11.5% lower than the same month last year. This decrease was primarily due to the reduction in business days in January due to the comparatively earlier Chinese New Year holiday in 2020. The extended holiday due to the unfortunate outbreak of the novel coronavirus first identified in Wuhan, China also affected our sales results. January 2020 deliveries consisted of 1,493 ES6s, the company's 5-seater high-performance premium electric SUV, and 105 ES8s, the company's 7-seater high-performance premium electric SUV and its 6-seater variant. Total aggregate deliveries of the ES6 and the ES8 reached 33,511 vehicles.

05:48 EST KKR sells Deutsche Glasfaser to EQT and OMERS - KKR announces the signing of an agreement with EQT Infrastructure IV fund and OMERS, for EQT and OMERS to jointly acquire Deutsche Glasfaser, or DG. Deutsche Glasfaser was founded in 2011 and KKR acquired a majority position in 2015 from Dutch investor Reggeborgh. Under KKR's ownership, Deutsche Glasfaser has become the fastest growing provider of gigabit internet connections through fiber-to-the-home, or FTTH, in Germany. With KKR's operational and financial support the company invested over EURO$1.2bn in fibre infrastructure and deployment in underserved rural and suburban communities in Germany, increasing connections to more than 600,000 households and 5,000 businesses. The investment in Deutsche Glasfaser was made through KKR's Infrastructure Fund II. KKR has been active in the infrastructure sector for a decade and currently has around $20bn AUM. The global infrastructure platform has completed over 30 investments in that period, half of those in Europe, across the energy and utility, transportation and telecommunications sectors. The team is currently investing KKR Global Infrastructure Investors III, a $7.4B vehicle raised in 2018, and has been active in Europe in recent months with transactions including the acquisition of a majority stake in Hyperoptic, a leading UK fibre broadband provider. The closing of the transaction is expected in Q2.

05:17 EST Inflow Technologies withdraws from acquisition by Tech Data - Tech Data announced that Inflow Technologies has exercised its right to withdraw from closing its acquisition by Tech Data. As a result, Inflow has paid a break fee to Tech Data, as outlined in the original acquisition agreement, which was announced on December 16, 2019.